Journal
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
Volume 31, Issue 1, Pages 83-+Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.hoc.2016.08.003
Keywords
Non-small cell lung cancer; Epidermal growth factor receptor (EGFR); Tyrosine kinase inhibitors (TKI); TKI resistance; Osimertinib; Gefitinib; Erlotinib; Afatinib
Categories
Ask authors/readers for more resources
Activating mutations in the epidermal growth factor receptor (EGFR) are present in approximately 15% of US patients with lung adenocarcinoma. EGFR tyrosine kinase inhibitors are associated with high response rate and progression-free survival for patients with non-small cell lung cancer with this genotype. Gefitinib, erlotinib, and afatinib are the EGFR tyrosine kinase inhibitors that are presently in clinical use. Understanding resistance mechanisms has led to the identification of a secondary mutational target, T790M, in more than half of patients, for which osimertinib has been approved. This article reviews the current treatments, resistance mechanisms, and strategies to overcome resistance.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available